Some studies have demonstrated increased ABCB1 expression in the advanced stages of CML, as well as the relationship between higher ABCB1 expression and a lower rate of imatinib resistance [64,65,66]. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.